The Scientific Committee for the “Cancer Immunotherapy – Emerging Targets to Unleash the Immune Response against Cancer” Workshop 2018 is now accepting abstract submissions for presentation at the conference on the 12 and 13 October 2018 (Doha, Qatar).

This highly specialized event will bring together a number of international and local expert speakers who will discuss and present on a wide range of research topics in the important field of cancer immunology including:

  • Immune checkpoint inhibitors
  • Radio/chemo/immunotherapy
  • Tumor antigens and vaccines
  • Immunomodulation and vaccines
  • Biomarkers in cancer immunotherapy
  • Pathological and pharmacological toxicities related to cancer immunotherapy
  • Innovative technologies in pathology, molecular epidemiology and virus related cancers
  • MicroRNA and functional proteomics 
  • Topics pertinent to the care and management of cancer patients and Immunotherapy.

Abstract submission opened on 26 June 2018 and closes on 6 September 2018 at 11pm. Abstracts should be submitted via e- mail to: [email protected] and [email protected]​ You should receive an email confirming receipt of your submission. Please contact us if you do not receive a reply. Decisions will be communicated by 16 September 2018.  Information about abstract submissions

  • All abstracts related to the above categories are eligible for submission. 
  • Abstracts should be submitted via the official conference abstract submission process. 
  • The abstract should include a title, author name(s), affiliation, background, method, results and conclusion. Proposals for presentations should identify the presenting author as the main contact (please complete the abstract submission template).
  • Word limit for the abstract is 250 words.
  • There is no limit to the number of abstracts an author may submit. 
  • Abstract submissions should be for research that is either complete or will be completed no later than the date of the conference.  
  • The Abstract Review Committee will review the abstract for relevance, validity, originality, special merit or other considerations.

If you have any queries about submitting an abstract, please send an email to one of the email addresses listed above. 

More Abdulqadir J. Nashwan's questions See All
Similar questions and discussions